Efficacy and safety of topical brepocitinib for the treatment of mild‐to‐moderate atopic dermatitis: a phase IIb, randomized, double‐blind, vehicle‐controlled, dose‐ranging and parallel‐group study

BACKGROUND: Atopic dermatitis (AD) is a prevalent inflammatory, pruritic skin disease. The Janus kinase (JAK) pathway is a treatment target. OBJECTIVES: To assess the efficacy, safety and pharmacokinetics of topical cream brepocitinib, a small‐molecule tyrosine kinase 2 (TYK2)/JAK1 inhibitor, in par...

Descripción completa

Detalles Bibliográficos
Autores principales: Landis, Megan N., Arya, Mark, Smith, Stacy, Draelos, Zoe, Usdan, Lisa, Tarabar, Sanela, Pradhan, Vivek, Aggarwal, Sudeepta, Banfield, Christopher, Peeva, Elena, Vincent, Michael S., Sikirica, Vanja, Xenakis, Jason, Beebe, Jean S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092158/
https://www.ncbi.nlm.nih.gov/pubmed/35986699
http://dx.doi.org/10.1111/bjd.21826

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10092158/
https://www.ncbi.nlm.nih.gov/pubmed/35986699
http://dx.doi.org/10.1111/bjd.21826

Ejemplares similares